TSHR; | |
CDA; TK1; AKR1B1; ALOX15; AKR1B10; | |
TRPA1; | |
CA12; CA9; | |
PTGS1; XDH; | |
CASP1; CASP7; | |
HIF1A; | |
SLC28A1; SLC28A3; | |
LMNA; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.008E-15 | 1.961E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.143E-10 | 2.240E-06 | ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.512E-10 | 2.337E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.779E-09 | 3.875E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.442E-09 | 5.765E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.894E-09 | 7.690E-06 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.926E-09 | 8.378E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.057E-08 | 1.129E-05 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.917E-08 | 5.793E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.356E-06 | 8.438E-04 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 1.138E-03 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.512E-06 | 1.436E-03 | CASP1, CASP7, MAPT, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.571E-06 | 1.436E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.066E-06 | 1.967E-03 | CYP2D6, CYP3A4 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 4.066E-06 | 1.967E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.892E-05 | 8.239E-03 | AKR1B1, AKR1B10, XDH |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 6.722E-05 | 2.121E-02 | AKR1B1, HIF1A, MAPT |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.854E-05 | 2.132E-02 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1, SLC28A3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.472E-10 | 7.510E-09 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.341E-08 | 5.680E-07 | CYP2C9, CDA, AKR1B10, CYP1A2, ALOX15, AKR1B1, TK1, CYP2C19, CYP3A4, XDH, PTGS1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.352E-08 | 3.448E-07 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.563E-07 | 1.993E-06 | CYP2C9, CYP2D6, ALOX15, CYP2C19, PTGS1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 2.100E-07 | 2.142E-06 | CDA, TK1, CYP3A4, XDH |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 7.092E-07 | 6.028E-06 | CYP2C9, ALOX15, CYP2C19, PTGS1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.372E-06 | 9.997E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.190E-06 | 1.396E-05 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.539E-05 | 2.825E-04 | CYP2C9, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.876E-03 | 5.893E-03 | TSHR, PTGS1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.810E-03 | 5.893E-03 | CASP7, CASP1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00561 | Glycerolipid metabolism | 2.080E-03 | 5.893E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 7.783E-04 | 2.835E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.396E-04 | 2.293E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.011E-03 | 5.893E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 6.144E-04 | 2.410E-03 | AKR1B10, AKR1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 3.336E-03 | 8.954E-03 | CASP7, CASP1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.703E-04 | 7.893E-04 | CA12, CA9 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.262E-05 | 7.154E-05 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Solid tumours | C00-D48 | TK1; CDA; CA9; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; |
C00-D49: Neoplasms | Prostate cancer | C61 | TK1; |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | TK1; CA9; |